Research Analysts Set Expectations for CRBP Q3 Earnings

Posted by Stanley Muller on Aug 11th, 2026

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Free Report) – Stock analysts at HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Friday, August 7th. HC Wainwright analyst A. Maldonado now forecasts that the biopharmaceutical company will post earnings per share of ($1.57) for the quarter, down from their previous estimate of ($1.26). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.87) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q4 2026 earnings at ($1.50) EPS, FY2026 earnings at ($6.11) EPS, FY2027 earnings at ($6.83) EPS, FY2028 earnings at ($5.56) EPS, FY2029 earnings at ($2.07) EPS and FY2030 earnings at $0.15 EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.26) by ($0.55).

CRBP has been the subject of several other research reports. Wall Street Zen lowered shares of Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Friday, July 17th. Guggenheim reissued a “buy” rating on shares of Corbus Pharmaceuticals in a research note on Tuesday, May 26th. Mizuho reduced their target price on shares of Corbus Pharmaceuticals from $44.00 to $34.00 and set an “outperform” rating for the company in a report on Tuesday, June 23rd. Finally, Wedbush decreased their price target on shares of Corbus Pharmaceuticals from $38.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 27th. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $41.12.

Check Out Our Latest Report on Corbus Pharmaceuticals

Corbus Pharmaceuticals Trading Down 7.0%

Shares of Corbus Pharmaceuticals stock opened at $9.46 on Tuesday. The company’s 50-day moving average price is $8.76 and its two-hundred day moving average price is $9.06. Corbus Pharmaceuticals has a 52 week low of $7.12 and a 52 week high of $20.56. The stock has a market cap of $175.29 million, a PE ratio of -1.53 and a beta of 2.59.

Insider Activity

In other Corbus Pharmaceuticals news, Director John Kenneth Jenkins sold 4,800 shares of the business’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $7.91, for a total transaction of $37,968.00. Following the sale, the director directly owned 3,833 shares of the company’s stock, valued at $30,319.03. The trade was a 55.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Yuval Cohen sold 17,000 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $10.08, for a total value of $171,360.00. Following the completion of the sale, the chief executive officer directly owned 157,316 shares of the company’s stock, valued at approximately $1,585,745.28. This trade represents a 9.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 38,238 shares of company stock valued at $365,393 in the last 90 days. Company insiders own 3.50% of the company’s stock.

Hedge Funds Weigh In On Corbus Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of CRBP. Persistent Asset Partners Ltd purchased a new stake in shares of Corbus Pharmaceuticals in the fourth quarter worth approximately $54,000. Virtu Financial LLC purchased a new position in Corbus Pharmaceuticals during the fourth quarter valued at approximately $88,000. Barclays PLC grew its position in Corbus Pharmaceuticals by 280.0% during the fourth quarter. Barclays PLC now owns 14,758 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 10,874 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in Corbus Pharmaceuticals in the 3rd quarter valued at approximately $129,000. Finally, Bank of America Corp DE increased its stake in Corbus Pharmaceuticals by 53,592.3% in the 1st quarter. Bank of America Corp DE now owns 13,960 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 13,934 shares during the period. Hedge funds and other institutional investors own 64.64% of the company’s stock.

Key Corbus Pharmaceuticals News

Here are the key news stories impacting Corbus Pharmaceuticals this week:

Positive Sentiment: HC Wainwright maintained a Buy rating and a $35 price target, implying substantial potential upside from recent trading levels despite reducing its earnings forecasts. Analysts continue to view Corbus’ pipeline, including lenabasum for inflammatory and fibrotic diseases, as a potential long-term catalyst. HC Wainwright Cuts Corbus Pharmaceuticals Price Target
Neutral Sentiment: Institutional ownership remains high at approximately 64.6%, with several investment firms increasing their positions in the latest reported quarter. However, these holdings are based on historical filings and may not reflect current positioning.
Negative Sentiment: HC Wainwright materially lowered its EPS outlook across multiple years: 2026 to -$6.11 from -$4.99, 2027 to -$6.83 from -$5.66, 2028 to -$5.56 from -$4.58, and 2029 to -$2.07 from -$1.13. Its 2030 forecast was reduced to just $0.15 from $1.29, while third- and fourth-quarter 2026 loss estimates also widened.
Negative Sentiment: Analysts have recently reduced price targets, including HC Wainwright to $35 from $40 and Oppenheimer to $48 from $52. Although both firms retain bullish ratings, the cuts suggest lower near-term expectations. Oppenheimer Cuts Corbus Pharmaceuticals Price Target
Negative Sentiment: Insider selling adds to investor caution. CEO Yuval Cohen sold 17,000 shares and CFO Sean Moran sold 12,000 shares at an average of $10.08, reducing their direct holdings by approximately 9.75% and 12.41%, respectively. Sean Moran Sells Corbus Pharmaceuticals Stock
Negative Sentiment: Corbus’ latest quarterly results showed a loss of $1.81 per share, wider than the $1.26 analyst consensus, reinforcing concerns about ongoing cash burn and the path to profitability.

Corbus Pharmaceuticals Company Profile

(Get Free Report)

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.